KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2025)

Historic Raw Materials for Rigel Pharmaceuticals (RIGL) over the last 5 years, with Q3 2025 value amounting to $7.0 million.

  • Rigel Pharmaceuticals' Raw Materials rose 34295.73% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 34295.73%. This contributed to the annual value of $1.1 million for FY2024, which is 7663.27% down from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Raw Materials of $7.0 million as of Q3 2025, which was up 34295.73% from $9.6 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Raw Materials peaked at $9.6 million during Q2 2025, and registered a low of $1.1 million during Q4 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' median Raw Materials value was $4.6 million (recorded in 2022), while the average stood at $4.6 million.
  • In the last 5 years, Rigel Pharmaceuticals' Raw Materials tumbled by 7663.27% in 2024 and then soared by 34876.46% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Raw Materials (Quarter) stood at $5.1 million in 2021, then dropped by 11.42% to $4.6 million in 2022, then increased by 1.19% to $4.6 million in 2023, then plummeted by 76.63% to $1.1 million in 2024, then surged by 545.31% to $7.0 million in 2025.
  • Its Raw Materials was $7.0 million in Q3 2025, compared to $9.6 million in Q2 2025 and $1.1 million in Q1 2025.